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Purpose: To evaluate the clinical safety and efficacy of povidone-iodine (PVP-I) 0.6%/
dexamethasone (DEX) 0.1% ophthalmic suspension vs vehicle in patients with clinically
suspected acute viral conjunctivitis.
Patients and methods: This was a randomized, double-masked, parallel-group, vehiclecontrolled study. Adults with a clinical diagnosis of suspected acute viral conjunctivitis were
randomized 1:1 to PVP-I/DEX ophthalmic suspension or vehicle bilaterally four times daily
for 5 days (Days 1–5). Evaluation was on Days 1, 3 (+1-day window), and 6 (+1). Patients with
signs of acute viral conjunctivitis at the Day 6 visit received open-label PVP-I/DEX for five
additional days and were evaluated on Day 11–14. The primary efficacy endpoint was clinical
resolution of acute viral conjunctivitis in the study eye at the Day 6 visit.
Results: Overall, 132 patients were randomized and received treatment (PVP-I/DEX, n=66;
vehicle, n=66); 38 patients continued into the open-label portion of the study. Not enough
patients with confirmed adenoviral conjunctivitis (n=32/132) were enrolled to assess the primary
endpoint, although there were some efficacy trends in the PVP-I/DEX group for global clinical
score (sum of watery conjunctival discharge and bulbar conjunctival redness). There were no
serious treatment-emergent adverse events (TEAEs) and no patients discontinued due to a TEAE.
In the masked phase, 56.1% of patients receiving PVP-I/DEX experienced at least one TEAE
vs 43.9% in the vehicle group; 78.9% of patients in the open-label phase experienced at least
one TEAE. Most TEAEs were mild in severity.
Conclusion: PVP-I/DEX ophthalmic suspension administered for #14 days had a favorable
safety profile and was generally well tolerated.
Keywords: adenoviral conjunctivitis, dexamethasone, povidone-iodine, randomized
controlled trial

Introduction

Correspondence: Jay S Pepose
Pepose Vision Institute, 1815 Clarkson
Road, Chesterfield, MO 63017, USA
Fax +1 636 728 0093
Email jpepose@peposevision.com

535

submit your manuscript | www.dovepress.com

Clinical Ophthalmology 2019:13 535–544

Dovepress

© 2019 Pepose et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

http://dx.doi.org/10.2147/OPTH.S191275

Powered by TCPDF (www.tcpdf.org)

Infectious conjunctivitis is a common eye condition mainly caused by viruses and
bacteria.1 Adenovirus is a frequent cause of infectious conjunctivitis, with reported
rates of adenoviral conjunctivitis varying widely from 40% to 75% of all cases of
infectious conjunctivitis.2–4 Adenoviral conjunctivitis is a public health concern due to
its highly contagious nature.5 It is also associated with significant patient discomfort,
lost productivity, and in rare cases can lead to complications such as subepithelial
corneal infiltrates and permanent compromise of vision.6,7
Currently, there are no approved treatments for adenoviral conjunctivitis, with
therapeutic options being limited to supportive therapies and palliative measures.7
A novel ophthalmic suspension of povidone-iodine (PVP-I) 0.6% and dexamethasone
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(DEX) 0.1% is currently under clinical investigation. PVP-I
is an antiseptic with bactericidal, virucidal, and fungicidal
properties.8 DEX is a corticosteroid routinely used as a
topical ophthalmic suspension for the treatment of ocular
inflammation.9 Both components are approved for use in
other indications and have been shown to be safe and efficacious for use on the ocular surface in humans.10–13
Different ophthalmic formulations of PVP-I in combination with DEX have been investigated for the treatment
of conjunctivitis in early-stage studies. In an in vivo study
conducted in rabbits, PVP-I 0.4%/DEX 0.1% significantly
improved clinical scores and viral titers vs control treatments.14 In a randomized controlled trial of 122 patients with
presumed viral conjunctivitis, treatment with ophthalmic
PVP-I 0.4%/DEX 0.1% four times daily (QID) significantly
reduced the duration of conjunctivitis vs patients treated
with artificial tears.15 Similar results were obtained in a
randomized controlled trial of 74 patients with adenoviral
keratoconjunctivitis confirmed with polymerase chain reaction (PCR). In that study, significantly faster improvement
of clinical signs and adenoviral eradication (in 5–7 days) vs
the control groups were observed in patients treated with
PVP-I 1.0%/DEX 0.1%.16 In a recent Phase II randomized
controlled study of 176 patients with acute adenoviral conjunctivitis, ophthalmic administration of PVP-I 0.6%/DEX
0.1% for 5 days demonstrated statistical superiority to vehicle
for clinical resolution, adenoviral eradication, global clinical
score, and expanded clinical cure.17
This report presents the results of a Phase II randomized
controlled study conducted in Brazil to evaluate the clinical
safety and efficacy of PVP-I 0.6%/DEX 0.1% ophthalmic
suspension compared with vehicle in the treatment of patients
with clinical suspicion of acute viral conjunctivitis.

Materials and methods
Study design
This was a randomized, double-masked, parallel-group,
vehicle-controlled study that was planned across two medical
centers, although all patients were enrolled at a single site in
Brazil. Patients were randomized 1:1 to receive either PVP-I
0.6%/DEX 0.1% ophthalmic suspension or vehicle, instilled
as a single drop in both eyes QID for 5 days. The study consisted of four visits over 11–14 days. Visit 1 occurred on Day 1,
Visit 2 on Day 3+1-day window, Visit 3 on Day 6+1-day
window, and Visit 4 on Days 11–14 (ie, visit 3+5–7 days;
Figure 1). Visit 4 was only required for patients with signs
of acute viral conjunctivitis in the study eye at Visit 3, with
those patients receiving open-label PVP-I 0.6%/DEX 0.1%
for an additional 5 days (Figure 1). All study treatments were
supplied as sterile preserved suspensions or solutions and
were colored, labeled and packaged identically. Noncompliance was recorded as a protocol deviation if .20% of doses
during a given dosing period were missed.

Patients
Eligible patients were aged $18 years and had a best
spectacle-corrected visual acuity (BSCVA) of 0.60 logarithm
of the minimum angle of resolution (logMAR) or better in
each eye, reported signs of viral conjunctivitis for #5 days
before the study in at least one eye, clinical diagnosis of suspected acute adenoviral conjunctivitis in at least one eye, and
the presence of both watery conjunctival discharge and bulbar
conjunctival redness score of $1 in the same eye (0–3 scale;
0= absent/normal, 1= mild, 2= moderate, and 3= severe).
Exclusion criteria included the following: pregnancy
or nursing a child; known sensitivity to any components
of the investigational treatments; clinical signs, presence,
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Figure 1 Study design.
Abbreviations: DEX, dexamethasone; PVP-I, povidone-iodine.
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or a history of herpes simplex keratitis; presence of ocular
inflammation (eg, uveitis or iritis) or an ocular infection
other than acute viral conjunctivitis; steroid responders
with increased intraocular pressure or those with a history
of glaucoma or elevated intraocular pressure .21 mmHg.
In addition, patients with a history of recurrent corneal erosion syndrome or with active ulcerative keratitis, clinically
significant optic nerve defects visible upon non-dilated
fundus examination at baseline, uncontrolled systemic
disease, autoimmune disease, or debilitating disease were
excluded. The use of investigational devices, contact lenses,
and the following treatments were not allowed in the study:
corticosteroids (not including stable use of inhaled or nasal
corticosteroids and topical dermal steroids, except around
the eyes), topical ocular or systemic antivirals, or any other
topical ophthalmic solutions including tear substitutes
and diagnostics.

Efficacy assessments
The primary efficacy endpoint was clinical resolution of acute
viral conjunctivitis in the study eye at the Day 6 visit. Clinical
resolution was defined as the absence (score =0) of both bulbar conjunctival redness and watery conjunctival discharge.
Additional efficacy measurements included individual
measurement of watery conjunctival discharge and bulbar
conjunctival redness in the study eye, expanded clinical cure
(a score of 0 or 1 for both bulbar conjunctival redness and
watery conjunctival discharge, with at least one sign having
a score of 0), and global clinical score (sum of bulbar conjunctival redness and watery conjunctival discharge scores;
total score 0–6). Crossover infection to a fellow eye was also
recorded, based on the presence (scores .0) of both watery
conjunctival discharge and bulbar conjunctival redness (only
patients with one eye that did not show both signs of viral
conjunctivitis at baseline were included).
All patients had a Rapid Pathogen Screening (RPS)
Adeno-Detector Plus™ test (Rapid Pathogen Screening Inc.,
Sarasota, FL, USA) performed at the Day 1 visit on both
eyes to identify, in office, whether they were RPS positive or
negative. RPS-positive testing was not an inclusion criterion
for the study. Conjunctival swabs of both eyes were taken
at each visit using a flocked swab kit (Copan Diagnostics,
Murrieta, CA, USA) and frozen at -70°C until analysis.
Adenovirus testing with cell culture immunofluorescence
assay (CC-IFA) and quantitative PCR ($100 copies/mL
was positive) was conducted on samples from eyes that were
RPS positive at Visit 1.

Clinical Ophthalmology 2019:13
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Safety assessments
Adverse events (AEs; reported, elicited, and observed),
slit-lamp biomicroscopy, and BSCVA were documented
at all study visits. The definition of AEs included any preexisting medical condition that worsened after administration
of the study drug, for example, the significant worsening
of viral conjunctivitis. Treatment-emergent AEs (TEAEs)
were defined as events that occurred or worsened after the
first dose. BSCVA was assessed using an Early Treatment
Diabetic Retinopathy Study chart. Urine pregnancy test and
nondilated fundus exam were performed at all visits except
the Day 3 visit.

Statistical analyses
The primary population for the efficacy analysis was based
on the modified intention-to-treat (mITT) population, consisting of patients in the intention-to-treat (ITT) population
(randomized patients who received at least one dose of
study medication) who had at least one visit after the Day 1
visit, and had a score $1 for watery conjunctival discharge
and bulbar conjunctival redness scores in the same eye at
the Day 1 visit. An additional analysis population was the
viral-positive population, consisting of patients in the mITT
population with a positive adenoviral test at the Day 1 visit
in either eye by any method (RPS, CC-IFA, and/or quantitative PCR). The safety population consisted of randomized
patients who received at least one dose of study medication.
A chi-square or Fisher’s exact test (for expected
count ,5) was used to compare treatment groups with
respect to binary endpoints, and a 2-sample t-test was used
to compare groups with respect to continuous endpoints.
Testing was conducted at a two-sided 0.05 significance level.
Viral titer was assessed by quantitative PCR at each
follow-up visit and summarized in the study eye by treatment
group. The proportions of patients with a 3-point reduction
from baseline in viral titer (log 10 transformed scale) in the
two study arms were compared using a chi-squared test. If the
viral test was negative (ie, ,100 copies/mL), then the viral
titer was considered to be 0. Due to the nature of the titer data,
log base 10 transformations were performed on the raw data
before any analyses were performed. To account for a value
of 0 (ie, when the titer results are “negative”), 0.5 was added
to all values before the log 10 transformations were taken.
The study eye was preliminarily designated by the
investigator at the time of enrollment (baseline), based on
signs alone. If both eyes had signs of viral conjunctivitis
for #5 days before the baseline visit, the study eye was based
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on whichever eye had the greater cumulative score for watery
conjunctival discharge and bulbar conjunctival redness at
baseline. If both eyes had the same cumulative score, then
the baseline-designated study eye was the right eye. For the
analysis, in patients with only one eye with a positive adenoviral test by PCR and score $1 for watery conjunctival discharge
and bulbar conjunctival redness at baseline, the infected eye
was the study eye. If both eyes at baseline were positive for
adenoviral testing and had sign scores of $1, the eye with the
greater cumulative score for conjunctival discharge and redness
at baseline was the study eye. If both eyes had the same cumulative score, then the study eye was the right eye. For patients
with neither eye with a positive adenoviral test at baseline, the
baseline-designated study eye was defined as the study eye.
Because this was a Phase II study, formal sample size
calculations were not performed, but a sample size of 120
evaluable patients (60 per treatment arm) was deemed reasonable and appropriate for providing information for powering
future studies.

Results
Study population
The study was conducted between May 2013 and March 2014.
A total of 132 patients were randomized and 99 completed the
study (Figure 2). The safety and ITT populations contained
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Figure 2 Patient disposition.
Notes: The viral-positive population consisted of all patients in the modified ITT
population with a positive viral test at Visit 1 in either eye by any method (Rapid
Pathogen Screening, cell culture immunofluorescence assay, and/or quantitative
polymerase chain reaction).
Abbreviations: DEX, dexamethasone; ITT, intention-to-treat; PVP-I, povidone-iodine.
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Table 1 Demographics (ITT population)
Characteristic

PVP-I/DEX
n=66

Vehicle
n=66

All patients
N=132

Age, y, mean (SD)
Sex, n (%)
Male
Female
Ethnicity, n (%)
Hispanic or Latino
Race, n (%)
Asian
Black or African
American
White
Other

30.2 (9.34)

31.8 (10.39)

31.0 (9.87)

20 (30.3)
46 (69.7)

29 (43.9)
37 (56.1)

49 (37.1)
83 (62.9)

64 (97.0)

64 (97.0)

128 (97.0)

0
27 (40.9)

1 (1.5)
21 (31.8)

1 (0.8)
48 (36.4)

38 (57.6)
1 (1.5)

44 (66.7)
0

82 (62.1)
1 (0.8)

Abbreviations: DEX, dexamethasone; ITT, intention-to-treat; PVP-I, povidone-iodine.

all 132 patients, while the mITT population contained
115 patients. A total of 38 patients (PVP-I/DEX, n=18; vehicle,
n=20) continued into the open-label portion of the study.
The mean (SD) age across all patients in the ITT population was 31.0 (9.87) years. Most patients were female (62.9%)
and nearly all (97.0%) were of Hispanic or Latino ethnicity
(Table 1). Four patients in the vehicle group and five in the
PVP-I/DEX group were recorded as noncompliant with dosing. Altogether, 131 (99.2%) patients had a primary clinical
diagnosis of viral conjunctivitis. With the exception of the
primary diagnosis, the most common (.5%) occurrences
in ocular medical history for all patients were eyelid edema
(22.0%), optic nerve disorders (12.1%), keratitis (9.8%),
corneal infiltrates (6.8%), and pinguecula (5.3%). The most
common nonocular medical history included hypertension
(5.3%), postmenopause (4.5%), female sterilization (3.0%),
rhinitis (2.3%), gastritis (2.3%), and diabetes mellitus (2.3%).

Viral status
Confirmatory adenovirus testing was planned to be carried
out on baseline RPS-positive eyes at each visit using CC-IFA
and quantitative PCR. At baseline, adenovirus testing was
conducted on 27 and 23 mITT patients in the PVP-I/DEX
and vehicle groups, respectively. Of these, adenovirus was
detected by CC-IFA and/or quantitative PCR in either eye of
59.3% (16/27) and 69.6% (16/23) of patients in the PVP-I/
DEX and vehicle groups, respectively. At the Day 3 visit,
73.7% (14/19) and 77.8% (14/18) of patients in those groups
were adenovirus positive. At the Day 6 visit, 70.6% (12/17)
and 77.8% (14/18) of patients were adenovirus positive.
At the Day 11–14 visit, 50.0% (6/12) and 45.5% (5/11) of
patients were adenovirus positive, respectively. The two
treatment groups were not statistically different from each
other in viral status at any visit.
Clinical Ophthalmology 2019:13
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Efficacy

Clinical resolution
Analysis in the mITT population with last observation carried
forward (LOCF) showed no statistical difference between the
PVP-I/DEX and vehicle groups at the Day 6 visit for clinical
resolution (66.1% [39/59] PVP-I/DEX vs 58.9% [33/56]
vehicle; P=0.4268). The proportions of patients with resolution of individual conjunctival signs in the study eye at the
Day 6 visit were numerically higher in the PVP-I/DEX group
compared with the vehicle group, but the difference was not
statistically significant (watery conjunctival discharge, 76.3%
[45/59] PVP-I/DEX vs 62.5% [35/56] vehicle; P=0.1087;
bulbar conjunctival redness, 67.8% [40/59] PVP-I/DEX vs
60.7% [34/56] vehicle; P=0.4280). Less than one-quarter
(24.2%; 32/132) of patients had confirmed adenoviral conjunctivitis in either eye at baseline, but an attempt was made
to analyze the data in these patients. At the Day 6 visit, in
the viral-positive population with LOCF, there were no statistically significant differences between treatment groups in
clinical resolution (33.3% [7/21] PVP-I/DEX vs 28.6% [6/21]
vehicle; P=0.7385), or in resolution of watery conjunctival

discharge (42.9% [9/21] PVP-I/DEX vs 33.3% [7/21] vehicle;
P=0.5251), or resolution of bulbar conjunctival redness (33%
[7/21] PVP-I/DEX vs 33.3% [7/21] vehicle; P=0.9999).
In the extension phase of the study (during which all
patients received open-label PVP-I/DEX after the Day 6
visit), 60.0% (9/15) of patients in the ITT population who
had received PVP-I/DEX before the Day 6 visit achieved
clinical resolution compared with 44.4% (8/18) who were in
the vehicle-treated group before the Day 6 visit; the betweengroup difference was not statistically significant (P=0.3733).
As with the masked part of the study, there were few patients
in the extension with confirmed adenoviral conjunctivitis, but
an attempt was made to analyze these data. In this limited
population, a positive adenoviral test did not appear to have
an impact on the response rate (54.5% [6/11] PVP-I/DEX
vs 50.0% [5/10] vehicle; P=0.8350).

Other efficacy endpoints
Viral titers were similar between the two treatment groups at
all visits in the viral-positive population. In this population,
at the Day 6 visit, 12.5% (2/16) of patients in the PVP-I/DEX
group achieved a 3-point reduction (log 10 transformed scale)
from baseline in viral titer in the study eye compared with
17.6% (3/17) of patients in the vehicle-treated group; the
difference was not statistically significant (P=0.9999). In the
mITT population, there were no reductions in viral conjunctivitis (study and fellow eyes) between the PVP-I/DEX and
vehicle treatment groups at any visit as measured by adenovirus (detected by CC-IFA or quantitative PCR) (Figure 3).

Positive quantitative PCR results (study eye)

Positive CC-IFA results (study eye)

100

100

72.7
64.0

60

82.4

82.4

14/17

14/17

82.4
75.0

80

14/17

12/16

16/22

16/25
45.5
5/11

40

50.0
5/10

Patients (%)

80

Patients (%)
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The agreement between the adenovirus tests was as
follows: 65.45% (36/55) of eyes tested for both RPS and
CC-IFA at baseline had consistent results between the two
tests. The agreement between the RPS and quantitative PCR
tests was 73.85% [48/65] of eyes tested at baseline; and
between the CC-IFA and quantitative PCR tests, the agreement was 72.68% [133/183] of eyes tested across all visits.

20

72.2
13/18

60

68.4
13/19

70.6
12/17

64.7
11/17

40

31.3
5/16

20

29.4
5/17
9.1

0

Day 1

Day 3+1

Treated
Days 1–5

Day 6+1

Days 11–14

1/11

0

Day 1

Open-label
extension

Day 3+1

Treated
Days 1–5
PVP-I/DEX

Day 6+1

0

Days 11–14

Open-label
extension

Vehicle

Figure 3 Adenovirus detection in the modified ITT population.
Notes: There were no significant differences in detected adenovirus between treatment groups at all visits. Positive is defined as $100 copies/mL for quantitative PCR and
“detected” virus for CC-IFA. Percentages are based on the number of eyes in each group with reported results. Values inside bars = number of eyes with positive result/total
number of eyes in each group with reported results.
Abbreviations: CC-IFA, cell culture immunofluorescence assay; DEX, dexamethasone; ITT, intention-to-treat; PCR, polymerase chain reaction; PVP-I, povidone-iodine.
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Table 2 Crossover infection to the fellow eye (mITT population)
Crossover infection

PVP-I/DEX n=59

Vehicle n=56

Any follow-up visit
n (%)
Day 3 visit
n (%)
Day 6 visit
n (%)
Day 11–14 visit
n (%)

n=20
2 (10.0)
n=18
2 (11.1)
n=19
0
n=1
0

n=17
4 (23.5)
n=17
4 (23.5)
n=16
1 (6.3)
n=3
0

Notes: Crossover infection is defined as the presence (scores .0) of both watery
conjunctival discharge and bulbar conjunctival redness. Only patients with one eye
that did not show both signs of viral conjunctivitis at baseline are included. n in the
header is the total number of patients enrolled in each treatment group within
the mITT population; n in the table is the number of patients with nonmissing data
and is used for calculating the percentages.
Abbreviations: DEX, dexamethasone; mITT, modified intention-to-treat; PVP-I,
povidone-iodine.

In the mITT population with LOCF, the percentage of
patients who met the definition of expanded clinical cure in
the study eye at the Day 6 visit was numerically higher in the
PVP-I/DEX group (76.3%; 45/59) compared with the vehicle
group (62.5%; 35/56); the difference was not statistically
significant (P=0.1087).
The proportion of patients with crossover infection, defined as the presence (scores .0) of both watery
conjunctival discharge and bulbar conjunctival redness, was
lower in the PVP-I/DEX group compared with the vehicle
group (Table 2).
In patients with a positive adenoviral test among the ITT
population, at the Day 3 visit, a reduction from baseline in
global clinical score (mean change, -1.5 vs 0.1; P=0.0078)
or the proportion of patients with any improvement from
baseline in global clinical score (75.0% [15/20] PVP-I/DEX
vs 30.0% [6/20] vehicle; P=0.0044) were significantly greater

with PVP-I/DEX compared with vehicle. Between-group
differences for the proportions of patients with a 3-point
reduction (25% [5/20] PVP-I/DEX vs 10% [2/20] vehicle)
or $50% reduction (40% [8/20] PVP-I/DEX vs 15% [3/20]
vehicle) from baseline in global clinical score were not
statistically significant at this time point. At the Day 6 visit
in this population, of the various measures of change from
baseline in global clinical score shown in Table 3, only
the proportion of patients in the PVP-I/DEX group with a
reduction of $50% from baseline was significantly greater
compared with the vehicle group (Table 3).
In the mITT population with LOCF, at the Day 6 visit, a
reduction from baseline in global clinical score or the proportion of patients with any improvement from baseline in global
clinical score were numerically greater with PVP-I/DEX vs
vehicle, although the differences were not significantly different (Table 3). Between-group differences for the proportion
of patients with a 3-point or $50% reduction from baseline
in global clinical score significantly favored PVP-I/DEX at
this time point (Table 3).

Safety
There were no serious AEs or deaths during the course of this
study and no patients discontinued as a result of an AE. In
addition, no patterns of AEs that suggested systemic toxicities or localized complications were identified. In the masked
phase of this study, of patients receiving PVP-I/DEX, 51.5%
(34/66) reported at least one ocular TEAE compared with
39.4% (26/66) in the vehicle group; 78.9% (30/38) of patients
in the open-label phase experienced at least one ocular TEAE.
Considerably fewer patients reported at least one nonocular
TEAE [masked phase, 4.5% (3/66) PVP-I/DEX vs 12.1%

Table 3 Change from baseline in global clinical score at Day 6 (+1-day window; study eye)

N
Mean (SD) score
P-value vs vehicle
Patients with a 3-point reduction from baseline, n (%)
P-value vs vehicle
Patients with a reduction of $50% from baseline, n (%)
P-value vs vehicle
Patients with any improvement from baseline, n (%)
P-value vs vehicle

ITT population with positive
adenoviral test

mITT population with LOCF

PVP-I/DEX n=21

Vehicle n=21

PVP-I/DEX n=59

Vehicle n=56

19
-2.3 (1.60)
0.1904
11 (57.9)
0.0791
14 (73.7)
0.0340
16 (84.2)
0.2733

20
-1.4 (2.58)

59
-3.1 (1.44)
0.1207
45 (76.3)
0.0061
52 (88.1)
0.0084
55 (93.2)
0.0895

56
-2.5 (2.22)

6 (30.0)
8 (40.0)
13 (65.0)

29 (51.8)
38 (67.9)
46 (82.1)

Notes: The global clinical score is the sum of watery conjunctival discharge and bulbar conjunctival redness, both assessed on integer scales of 0–3. Higher scores are
indicative of greater severity. n in the header is the total number of patients enrolled in each treatment group; n in the table is the number of patients with nonmissing data
and is used for calculating percentages where appropriate.
Abbreviations: DEX, dexamethasone; ITT, intention-to-treat; LOCF, last observation carried forward; mITT, modified intention-to-treat; PVP-I, povidone-iodine.
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Table 4 Summary of most frequent treatment-emergent adverse events (safety population)
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Masked phase

Patients with $1 TEAE
Ocular TEAEs
Mild
Moderate
Severe
Nonocular TEAEs
Mild
Moderate
Severe
Most frequent (.5%) ocular TEAEs
Corneal infiltrates
Eyelid edema
Keratitis
Instillation-site pain
Conjunctivitis viral
Most frequent (n.1) nonocular TEAEs
Headache
Dizziness

Open-label phase

PVP-I/DEX (n=66), n (%)

Vehicle (n=66), n (%)

PVP-I/DEX (n=38), n (%)

Study eyea

Study eyea

Study eyea

32 (48.5)
0
0

2 (3.0)
2 (3.0)
3 (4.5)
21 (31.8)
3 (4.5)

Fellow eyea

37 (56.1)
34 (51.5)
28 (42.4)
0
0
3 (4.5)
3 (4.5)
0
0
3 (4.5)
2 (3.0)
0
21 (31.8)
1 (1.5)

18 (27.3)
1 (1.5)
0

Fellow eyea

29 (43.9)
26 (39.4)
15 (22.7)
0
0
8 (12.1)
8 (12.1)
0
0

6 (9.1)
4 (6.1)
6 (9.1)
2 (3.0)
1 (1.5)

2 (3.0)
0

3 (4.5)
1 (1.5)
4 (6.1)
2 (3.0)
7 (10.6)
4 (6.1)
2 (3.0)

27 (71.1)
1 (2.6)
0

20 (52.6)
3 (7.9)
8 (21.1)
6 (15.8)
1 (2.6)

Fellow eyea

30 (78.9)
30 (78.9)
24 (63.2)
0
0
4 (10.5)
4 (10.5)
0
0
14 (36.8)
3 (7.9)
6 (15.8)
6 (15.8)
7 (18.4)
1 (2.6)
1 (2.6)

Notes: Percentages are based on the total number of patients in each treatment group. aWhere applicable.
Abbreviations: DEX, dexamethasone; PVP-I, povidone-iodine; TEAE, treatment-emergent adverse event.

(8/66) vehicle; open-label phase, 10.5% (4/38)]. The most
frequently reported ocular (.5% of patients) or nonocular
(.1 patient) TEAEs in either treatment group are presented
in Table 4. In the masked phase, all ocular and nonocular
TEAEs in the PVP-I/DEX group were considered to be mild
in severity. In the open-label extension, two ocular TEAEs
(reduced visual acuity and scarring) reported by 2.6% (1/38)
of patients receiving PVP-I/DEX were classified as moderate; all other TEAEs in the extension were considered to be
mild (Table 4).
In the masked phase, 34.8% (23/66) of patients in the
PVP-I/DEX group reported a total of 23 ocular TEAEs in
the study eye that were suspected to be related to the study
treatment. These were predominantly mild instillation-site
pain (21/23 ocular TEAEs). The most frequently reported
ocular TEAEs that were not suspected of being related to
study treatment in the PVP-I/DEX group included corneal
infiltrates (reported by 3.0% and 4.5% of patients in the study
eye and fellow eye, respectively), ocular pruritus (reported by
3.0% of patients in both the study eye and fellow eye), and
viral conjunctivitis (reported by 4.5% and 1.5% of patients
in the study eye and fellow eye, respectively). No nonocular
TEAEs were suspected to be related to treatment in the PVP-I/
DEX treatment group during the masked phase of the study.
In the open-label phase, ocular TEAEs (mild corneal
infiltrates, mild keratitis, and mild instillation-site pain)

Clinical Ophthalmology 2019:13

were reported in 78.9% (30/38) of patients. Four nonocular
TEAEs were reported in 10.5% (4/38) of the open-label–
treated patients. These were pyrexia, dizziness, headache,
and dysmenorrhea. Only the dizziness (mild in severity)
was suspected of being related to study treatment (Table 4).
In the masked and open-label phases of the study, the only
nonocular TEAEs that were reported in more than one patient
in any treatment group were headache and dizziness (Table 4).
Slit-lamp biomicroscopy examinations revealed several
cases of shifts from normal at baseline to abnormal (clinically
significant or nonclinically significant) at subsequent visits.
These shifts were noted across treatment groups and visits
predominantly for evaluations of the cornea. There were no
clinically significant abnormal findings with fundoscopic
examinations of the optic nerve after treatment with PVP-I/
DEX or vehicle. Mean changes in BSCVA over the course of
the study did not show any notable increases in score in any
treatment group; however, there were some individuals who
experienced a change in BSCVA of $0.22 logMAR (Day 3
visit, 0 PVP-I/DEX vs 7.4% [4/54] vehicle; Day 6 visit, 3.6%
[2/55] PVP-I/DEX vs 3.7% [2/54] vehicle; Day 11–14 visit,
5.0% [1/20] PVP-I/DEX vs 10.0% [2/20] vehicle).

Discussion
The present study intended to evaluate the superiority of
PVP-I/DEX ophthalmic suspension compared with vehicle
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for clinical resolution of acute viral conjunctivitis, but not
enough patients with confirmed adenoviral conjunctivitis
were enrolled to assess the primary efficacy endpoint for
PVP-I/DEX. An attempt was made to analyze the data on
patients with confirmed adenoviral conjunctivitis; however,
there was very little remaining statistical power to assess
efficacy. Overall, some trends toward efficacy were observed
for PVP-I/DEX, and the drug combination had a favorable
safety profile and was generally well tolerated in this study,
with no serious ocular TEAEs reported and no patients
withdrawn from the study due to an AE.
Less than one-quarter (n=32/132) of patients in this
study had confirmed adenoviral conjunctivitis at baseline
by CC-IFA or quantitative PCR. A positive RPS AdenoDetector Plus test was not an inclusion criterion in this study,
which could explain the low number of adenoviral-positive
patients enrolled, because an accurate diagnosis of viral conjunctivitis based on clinical signs is known to be difficult.18
In contrast, in a Phase II efficacy and safety trial conducted
in India that included only RPS-positive patients, sufficient
numbers of patients with confirmed adenoviral conjunctivitis
were enrolled (81.8% of randomized patients) and PVP-I/
DEX demonstrated statistical superiority to vehicle for clinical resolution, adenoviral eradication, global clinical score,
and expanded clinical cure.17 In the present study, although
we were not able to assess the primary efficacy endpoint,
some improvements in global clinical scores were observed
following treatment with PVP-I/DEX in patients with a
positive adenoviral test among the ITT population and in the
mITT population with LOCF. PVP-I/DEX also appeared to
have a benefit relative to crossover infection rates, with lower
proportions of patients with crossover infection compared
with vehicle treatment.
The observed safety profile of PVP-I/DEX in this study
appeared to be consistent with the well-characterized safety
profiles of PVP-I and DEX, and no patterns of AEs indicative of systemic toxicities or localized complications were
identified. Overall, no serious AEs were reported and the
majority of TEAEs were ocular in nature and mild in severity.
Most of the AEs with a suspected relationship to treatment
with PVP-I/DEX consisted of mild instillation-site pain. All
nonocular TEAEs were mild and the only nonocular TEAEs
that occurred in more than one patient in any treatment group
were headache and dizziness. Importantly, no patients in this
study discontinued due to AEs. The safety and tolerability
results of the present study are consistent with results from
the study conducted in India.17 In both studies, there were
no increases in AEs that have been previously associated
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with the use of topical ocular corticosteroids, ie, increases in
intraocular pressure, cataract development, or glaucoma.19–21
Infectious conjunctivitis is a clinically challenging condition due to the overlap of symptoms between bacterial and
viral causes and because no treatment is approved for viral
conjunctivitis. A drug that treats both adenoviral and bacterial
conjunctivitis would mitigate the negative effects of misdiagnosis, which can occur in up to 50% of cases.22 Phase III
clinical trials are ongoing in adults and children to evaluate
the efficacy and safety of PVP-I 0.6%/DEX 0.1% in adenoviral conjunctivitis (NCT02998541 and NCT02998554).
Potential limitations of this study are that the study was
conducted in a single country and that serotyping was not
performed, which may limit the generalizability of the results.
In addition, according to the instructions of the RPS AdenoDetector Plus test used, the sensitivity of the test was 84%,
so negative test samples that were not subsequently tested
by quantitative PCR or CC-IFA could have been positive for
adenovirus or other viruses.
Future studies evaluating the efficacy of PVP-I/DEX
could be improved by modifying study eligibility criteria to
increase the likelihood of enrolling subjects with confirmed
adenoviral conjunctivitis. This may be achieved by the use of
the AdenoPlus® test as a screening test and/or better clinical
assessment criteria. A study with an adequate number of
subjects with adenoviral conjunctivitis confirmed by culture
would enable a robust assessment of efficacy.

Conclusion
The QID dosing of PVP-I 0.6%/DEX 0.1% ophthalmic suspension for #14 days was generally well tolerated, with no
unexpected TEAEs, and a safety profile that was consistent
with the known pharmacological profile of PVP-I and DEX.
Overall, some trends toward efficacy were observed for
PVP-I/DEX, but large Phase III trials enrolling a high proportion of patients with confirmed adenoviral conjunctivitis
are needed to further evaluate the efficacy of this product
for adenoviral conjunctivitis. Such studies are ongoing and
should provide important information.
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This trial was compliant with the principles of the Declaration
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observation carried forward; logMAR, logarithm of the
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Screening; TEAE, treatment-emergent adverse event.
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